구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Liso-cel |
Overview Company | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Relapsed or Refractory Follicular Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | A new era for transplant-ineligible R/R LBCL patients: what's changing?. Most patients with large B-cell lymphoma (LBCL) are cured with frontline chemoimmunotherapy; however, 30-40% experience relapsed or refractory (R/R) disease. Historically, salvage chemotherapy followed by autologous stem cell transplantation (ASCT) represented the standard second-line treatment. Several studies have demonstra… |
Toxicology CRS | Reported |
Clinical Safety signal | A new era for transplant-ineligible R/R LBCL patients: what's changing?. Most patients with large B-cell lymphoma (LBCL) are cured with frontline chemoimmunotherapy; however, 30-40% experience relapsed or refractory (R/R) disease. Historically, salvage chemotherapy followed by autologous stem cell transplantation (ASCT) represented the standard second-line treatment. Several studies have demonstra… |
Clinical Selected reported efficacy | ORR 53.7% |
Clinical Reported ORR | 53.7% |
Clinical Result source | ClinicalTrials.gov NCT03744676 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03744676 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Liso-cel |
Overview Company | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Relapsed or Refractory Follicular Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | A new era for transplant-ineligible R/R LBCL patients: what's changing?. Most patients with large B-cell lymphoma (LBCL) are cured with frontline chemoimmunotherapy; however, 30-40% experience relapsed or refractory (R/R) disease. Historically, salvage chemotherapy followed by autologous stem cell transplantation (ASCT) represented the standard second-line treatment. Several studies have demonstra… |
Toxicology CRS | Reported |
Clinical Safety signal | A new era for transplant-ineligible R/R LBCL patients: what's changing?. Most patients with large B-cell lymphoma (LBCL) are cured with frontline chemoimmunotherapy; however, 30-40% experience relapsed or refractory (R/R) disease. Historically, salvage chemotherapy followed by autologous stem cell transplantation (ASCT) represented the standard second-line treatment. Several studies have demonstra… |
Clinical Selected reported efficacy | ORR 53.7% |
Clinical Reported ORR | 53.7% |
Clinical Result source | ClinicalTrials.gov NCT03744676 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03744676 |
추천 비교
추천 비교